Further analysis indicated that AXL inhibition upregulated expression of PD-L1 and MHC I (on murine tumor cells) and PD-1 (on T cell populations) and that AXL inhibition, using bemcentinib or SGI-7079, combined with PD-1 blockade resulted in cure of ID8 and 4T1 tumor-bearing mice. Here, PDCD1 is linked to neoplasm.